TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35292486
Drug: 3-hour training
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-hour training for neurologists on how to provide complex information about MS escalation therapy
Study: 32788041
Drug: Subcutaneous border
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous border plating (± hook)
Study: 35300506
Drug: Azelastine add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine add-on therapy and Budesonide nasal spray
Study: 35300506
Drug: Montelukast add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast add-on therapy and Budesonide nasal spray
Study: 35300506
Drug: Intranasal Budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal Budesonide spray with placebo tablet (Control)
Study: 35738244
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of Dialectical Behavior Therapy (DBT-6)
Study: 35738244
Drug: 12 months
Normalized name: Elecare HMO 0-12 Months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 months of Dialectical Behavior Therapy (DBT-12)
Study: 33823285
Drug: Rovalpituzumab tesirine
Normalized name: Rovalpituzumab tesirine
DrugBank: Rovalpituzumab tesirine (DB13017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rovalpituzumab tesirine (Rova‐T) 0.3 mg/kg every 6 weeks (omitted every third cycle)
Study: 32645213
Drug: Adjunctive perampanel
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjunctive perampanel (maximum dose = 12 mg/d)
Study: 36167895
Drug: Silicon (Si)
DrugBank: Silicon (DB12982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicon (Si) at 1.2 mmol L‐1
Study: 36167895
Drug: Silicon (Si)
DrugBank: Silicon (DB12982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicon (Si) at 2.4 mmol L‐1
Study: 36167895
Drug: Silicon (Si)
DrugBank: Silicon (DB12982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicon (Si) at 3.6 mmol L‐1
Study: 36167895
Drug: Silicon (Si)
DrugBank: Silicon (DB12982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicon (Si) at 1.2, 2.4, and 3.6 mmol L‐1
Study: 36167895
Drug: Silicon (Si)
DrugBank: Silicon (DB12982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicon (Si) at all concentrations (1.2, 2.4, and 3.6 mmol L‐1)
Study: 36419123
Drug: Diesel exhaust
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diesel exhaust (DE) exposure at 150 µg/m3 PM2.5 for 4 hours
Study: 36419123
Drug: Diesel exhaust
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diesel exhaust (DE) exposure at varying concentrations (20, 50, 150 µg/m3 PM2.5)
Study: 33880724
Drug: Accelerated Partial
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated Partial Breast Irradiation (APBI) - 3D conformal external irradiation, 3.75 Gy/fraction, twice a day, 5 fractions/week, total dose 37.5 Gy
Study: 33880724
Drug: Whole Breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole Breast Irradiation (WBI) - 3D conformal external irradiation, 2 Gy daily/fraction, 5 fractions/week, total dose 50 Gy
Study: 33322629
Drug: Bovine milk-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine milk-based multicomponent fortifier and protein supplement
Study: 33322629
Drug: Donkey milk-derived
Normalized name: Recombinant human C1-inhibitor rabbit milk derived
DrugBank: Conestat alfa (DB09228)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Donkey milk-derived multicomponent fortifier and protein supplement
Study: 32984909
Drug: Oral plus
Normalized name: Acetaminophen/Dexbrompheniramine Maleate/Pseudoephedrine Hydrochloride 500 MG-3 MG-60 MG Oral Tablet, Extended Release [DRIXORAL PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral plus intravenous (IV) antibiotic prophylaxis (AP) - oral erythromycin 500 mg + metronidazole 500 mg a day before surgery and 1,000 mg of cephalosporin IV 30–90 min before operation
Study: 32984909
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) antibiotic prophylaxis only
Study: 35644960
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia with 1% tetracaine
Study: 35277087
Drug: E5 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: E5 group (0.25 mg/kg i.v. loading dose of esmolol, followed by 5 µg/kg/min infusion)
Study: 35277087
Drug: E10 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: E10 group (0.5 mg/kg i.v. loading dose of esmolol, followed by 10 µg/kg/min infusion)
Study: 34474441
Drug: Ketamine by
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine by intravenous continuous infusion (0.25 mg/kg/h)
Study: 34474441
Drug: Ketamine by
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine by intravenous bolus (0.25 mg/kg every hour)
Study: 34474441
Drug: Ketamine by
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine by intravenous bolus
Study: 34474441
Drug: Ketamine by
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine by intravenous continuous infusion
Study: 33893522
Drug: Cell therapy
Normalized name: hRPE cell therapy
DrugBank: ASP-7317 (DB18549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell therapy (mesenchymal stem cells)
Study: 34228877
Drug: Intralesional Candida
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional Candida antigen (0.3 ml injection)
Study: 34228877
Drug: Intralesional vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional vitamin D3 (0.6 ml, 60,000 IU injection)
Study: 34228877
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (0.3 ml injection)
Study: 32481563
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg red Korean ginseng extract per day for seven days
Study: 36196711
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline solution (HSS) infusion plus standard diuretics therapy (SDT)
Study: 36196711
Drug: Etilefrine tablets
Normalized name: etilefrine
DrugBank: Etilefrine (DB08985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etilefrine tablets plus standard diuretics therapy (SDT)
Study: 36196711
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of HSS infusion and etilefrine tablets plus standard diuretics therapy (SDT)
Study: 36196711
Drug: Standard diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard diuretics therapy (SDT) alone
Study: 32654558
Drug: No beta-blocker
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No beta-blocker therapy
Study: 34866258
Drug: Oral dextrose
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dextrose as first line treatment
Study: 34866258
Drug: Re-checking blood
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-checking blood glucose concentrations after oral dextrose
Study: 34866258
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of intravenous dextrose
Study: 34088224
Drug: 30% oral
Normalized name: Lactobacillus Acidophilus/Lactobacillus Bifidus 70%-30% Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% oral glucose solution (GG)
Study: 32865148
Drug: PST-Hospice (Brief
Approvals — FDA: no, EMA: no, PMDA: no
Description: PST-Hospice (Brief Problem-Solving Therapy)
Study: 36401749
Drug: Add-on Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Add-on Celecoxib 400 mg/day
Study: 33478570
Drug: Silver needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver needle therapy (SNT) and physiotherapy
Study: 33478570
Drug: Silver needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver needle therapy (SNT)
Study: 33070152
Drug: Fenofibrate 10
Normalized name: fenofibrate 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 10 mg/kg/day for 1 day or 2 days
Study: 34618982
Drug: Omega-3 free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 free carboxylic acids (OM-3CA) 4 g per day
Study: 38837237
Drug: Doxepin cream
Normalized name: doxepin Topical Cream
DrugBank: Doxepin (DB01142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxepin cream
Study: 35749440
Drug: Telehealth behaviour
Normalized name: Guaifenesin 100 mg in 5 mL ORAL LIQUID [SelectHealth Tussin DM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telehealth behaviour intervention (3 times per week for 12 weeks, including home-based exercise twice a week and individual lifestyle program once a week)
Study: 37586845
Drug: Colchicine treatment
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine treatment
Study: 32476162
Drug: Eflapegrastim 13.2
Normalized name: EFLAPEGRASTIM 13.2 mg in 0.6 mL SUBCUTANEOUS INJECTION, SOLUTION [Rolvedon]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eflapegrastim 13.2 mg (3.6 mg G-CSF)
Study: 32476162
Drug: Pegfilgrastim 6
Normalized name: PEGFILGRASTIM 6MG/0.6ML DELIVERY KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegfilgrastim 6 mg G-CSF
Study: 33958268
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg/day for 14 weeks
Study: 36549749
Drug: Common Elements
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common Elements Treatment Approach (CETA)
Study: 35594631
Drug: Concentrated fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrated fish oil (FO) 3 g/d
Study: 35594631
Drug: Corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil (CO) 3 g/d
Study: 35229616
Drug: Ticagrelor monotherapy
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor monotherapy after 1 month (with aspirin for the first month)
Study: 35229616
Drug: Standard dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dual antiplatelet therapy for 1 year followed by aspirin alone
Study: 35229616
Drug: Standard dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dual antiplatelet therapy
Study: 34678198
Drug: Typhoid Conjugate
Normalized name: Typhoid conjugate vaccine (TCV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typhoid Conjugate Vaccine (TCV)
Study: 34187937
Drug: Intra-articular Corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular Corticosteroid Injection (IACI) with 40mg Triamcinolone and 1ml 2% Lignocaine
Study: 33284237
Drug: nal‐IRI 50 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: nal‐IRI 50 mg/m2 every 2 weeks + TMZ 50 mg/m2/d
Study: 33284237
Drug: nal‐IRI 70 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: nal‐IRI 70 mg/m2 every 2 weeks + TMZ 50 mg/m2/d
Study: 32085778
Drug: Open-abdomen (OA)
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-abdomen (OA) approach with active negative pressure peritoneal therapy
Study: 34663672
Drug: Daily mobile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily mobile phone instructional text messages to perform regular outdoor walking and functional leg exercises (n=40)
Study: 35499216
Drug: Telitacicept (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telitacicept (80 or 160 mg per week)
Study: 33186125
Drug: Integrated yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated yoga therapy (performed 3 to 4 times weekly at home with 1 in-office session weekly for the first month)
Study: 33186125
Drug: Integrated yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated yoga therapy
Study: 34496755
Drug: Perineural dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perineural dexamethasone 4 mg with 0.5% ropivacaine
Study: 34496755
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone 4 mg
Study: 36159553
Drug: Qigong (QG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qigong (QG) rehabilitation therapy
Study: 36159553
Drug: Routine cardiologic
Normalized name: Cardiology Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine cardiologic medication (Control)
Study: 33287570
Drug: Curcuma longa
Normalized name: Curcuma Longa
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuma longa and Boswellia serrata extracts (two tablets twice a day for 1 month)
Study: 35548913
Drug: tiapride, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiapride, 100 mg twice daily
Study: 35548913
Drug: topiramate, 25
Normalized name: Topiramate, 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: topiramate, 25 mg twice daily
Study: 33148343
Drug: Implementation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implementation of evidence-based protocols for stroke management in the ED, including triage, administration of tissue plasminogen activator, management of fever, hyperglycaemia, and swallowing, and transfer to a stroke unit.
Study: 34195864
Drug: ThrIVe-B intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: ThrIVe-B intervention plus treatment as usual
Study: 32340616
Drug: Automated digital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated digital reminders + personalized prescribed treatment plan (pPTP)
Study: 37104214
Drug: Proton-Pump Inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton-Pump Inhibitors (PPIs)
Study: 34112266
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care based on intensive insulin therapy
Study: 32949255
Drug: Continuous IV
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous IV butylscopolamine 100 mg/24 h
Study: 32007230
Drug: Ticagrelor +
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor + Aspirin for 3 months, then Ticagrelor alone for 9 months
Study: 32007230
Drug: Clopidogrel +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel + Aspirin for 3 months, then Clopidogrel alone for 9 months
Study: 33512799
Drug: Low-dose GLP-2
Normalized name: (Gly2)GLP-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose GLP-2 (1 pmol × kg × min)
Study: 33512799
Drug: High-dose GLP-2
Normalized name: (Gly2)GLP-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose GLP-2 (10 pmol × kg × min)
Study: 34245356
Drug: Signal Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Signal Daily White (SDW)
Study: 32506363
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis (IVT) with idarucizumab reversal in dabigatran-treated patients
Study: 36086723
Drug: Lidocaine (2%)
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine (2%) 1.5 mg/kg bolus before induction followed by 2 mg/kg/h continuous infusion up to skin closure
Study: 36326756
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg dose of ERBB2 ICD plasmid-based vaccine
Study: 36326756
Drug: 500 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 μg dose of ERBB2 ICD plasmid-based vaccine
Study: 36326756
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg and 500 μg doses of ERBB2 ICD plasmid-based vaccine
Study: 36326756
Drug: Highest vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest vaccine dose (500 μg)
Study: 33616843
Drug: Aloe vera
Normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloe vera 3% ointment, 1 g twice daily for 6 weeks
Study: 32044621
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 50 mg
Study: 33710717
Drug: Oral semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral semaglutide (14 mg)
Study: 32055016
Drug: 24 GyE
Normalized name: DIMETHICONE 0.6 g in 100 mL TOPICAL SHAMPOO [GYEOL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 GyE proton beam therapy (PBT) with intravitreal anti-VEGF therapy
Study: 32055016
Drug: 24 GyE
Normalized name: DIMETHICONE 0.6 g in 100 mL TOPICAL SHAMPOO [GYEOL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 GyE proton beam therapy (PBT)
Study: 35589614
Drug: SGLT2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT2 inhibitors (meta-analysis)
Study: 32475902
Drug: Repaglinide monotherapy
Normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repaglinide monotherapy
Study: 35934637
Drug: Sub-epidermal moisture
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-epidermal moisture scanning (SEMS) daily
Study: 35934637
Drug: Routine pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine pressure injury prevention care and daily visual skin assessment
Study: 35180125
Drug: Fosgonimeton 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosgonimeton 40 mg in AD subjects (n=7)
Study: 35180125
Drug: Fosgonimeton (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosgonimeton (various doses) in healthy young males (n=48)
Study: 35180125
Drug: Fosgonimeton (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosgonimeton (various doses) in healthy elderly subjects (n=29)
Study: 35180125
Drug: Fosgonimeton (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosgonimeton (various doses)
Study: 32190990
Drug: Bimonthly ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bimonthly ranibizumab (0.5 mg intravitreal)
Study: 32190990
Drug: Treat-and-extend (T&E)
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treat-and-extend (T&E) ranibizumab (0.5 mg intravitreal)
Study: 32190990
Drug: Pro re
Normalized name: Blistex Pro Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pro re nata (PRN) ranibizumab (0.5 mg intravitreal)
Study: 34078520
Drug: Self-administered cryotherapy
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered cryotherapy
Study: 34193264
Drug: Melissa officinalis
Normalized name: melissa officinalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melissa officinalis syrup
Study: 36039762
Drug: MEDI6012 (2-
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI6012 (2- or 6-dose regimen)
Study: 36039762
Drug: MEDI6012 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI6012 (6 doses)
Study: 34753423
Drug: SCB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCB with mepivacaine 1%, 25-30 ml (n=30)
Study: 34753423
Drug: SCB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCB with ropivacaine 0.5%, 25-30 ml (n=30)
Study: 35675601
Drug: Adjunctive azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjunctive azithromycin initiated after skin incision
Study: 35675601
Drug: Adjunctive azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjunctive azithromycin initiated 0-30 minutes before skin incision
Study: 35675601
Drug: Adjunctive azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjunctive azithromycin initiated more than 30-60 minutes before skin incision
Study: 35675601
Drug: Adjunctive azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjunctive azithromycin initiated more than 60 minutes before skin incision
Study: 33403734
Drug: Low-dose remifentanil
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose remifentanil
Study: 33403734
Drug: High-dose remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose remifentanil
Study: 33598874
Drug: FF/UMEC/VI (100/31.25/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF/UMEC/VI (100/31.25/25 μg, 100/62.5/25 μg, 200/31.25/25 μg, 200/62.5/25 μg)
Study: 33598874
Drug: FF/VI (100/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF/VI (100/25 μg, 200/25 μg)
Study: 34649396
Drug: Social Intelligence
Normalized name: Intelence
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Social Intelligence Counseling Intervention (eight 1-hour weekly sessions)
Study: 34653648
Drug: Telepsychiatry group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telepsychiatry group (at least 50% of treatments via telemedicine, with at least one face-to-face treatment within six months)
Study: 34653648
Drug: Face-to-face (FTF)
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face (FTF) group (all treatments conducted FTF, with no telemedicine)
Study: 32233251
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (10 ml)
Study: 36387337
Drug: Pitavastatin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin (2 mg) oral tablets once daily for 6 months
Study: 36387337
Drug: Pitavastatin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin (2 mg) oral tablets once daily for 6 months (HER2 positive subgroup)
Study: 36387337
Drug: Pitavastatin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin (2 mg) oral tablets once daily for 6 months (HER2 negative subgroup)
Study: 33814391
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy with antioxidant medication
Study: 32345170
Drug: Investigational treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational treatment for RCC/UCC
Study: 35723686
Drug: Low-dose methylprednisolone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methylprednisolone (40 mg loading bolus followed by 40 mg/day for 7 days, then tapering over 20 days)